secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001641172-25-013038
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Zyversa receives Nasdaq delisting notice for low bid price; will appeal
-----------------------------------------------------------------------

- Received Nasdaq letter on May 27, 2025 for non-compliance with $1.00 minimum bid price rule.
- Ineligible for cure period due to two reverse stock splits in past two years (1:35 Dec 2023, 1:10 Apr 2024).
- Unless appeal requested by June 3, 2025, securities face delisting on June 5, 2025.
- Company intends to appeal and request hearing, which will stay delisting pending panel decision.
- No assurance of regaining compliance with continued listing requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000164117225013038/0001641172-25-013038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000164117225013038/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-013038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer